A detailed history of Artia Global Partners LP transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Artia Global Partners LP holds 433,580 shares of VKTX stock, worth $22.3 Million. This represents 7.15% of its overall portfolio holdings.

Number of Shares
433,580
Previous 383,580 13.04%
Holding current value
$22.3 Million
Previous $7.14 Billion 398.06%
% of portfolio
7.15%
Previous 2.08%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$17.4 - $94.5 $869,999 - $4.73 Million
50,000 Added 13.04%
433,580 $35.6 Billion
Q2 2023

Aug 14, 2023

BUY
$14.84 - $24.79 $4.68 Million - $7.81 Million
315,172 Added 460.72%
383,580 $6.22 Billion
Q1 2023

May 15, 2023

SELL
$8.08 - $17.33 $505,040 - $1.08 Million
-62,505 Reduced 47.75%
68,408 $1.14 Billion
Q4 2022

Feb 14, 2023

BUY
$2.72 - $9.4 $356,083 - $1.23 Million
130,913 New
130,913 $1.23 Billion

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.95B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Artia Global Partners LP Portfolio

Follow Artia Global Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Artia Global Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Artia Global Partners LP with notifications on news.